HBM Holdings Ltd. is an investment company, which engages in the discovery and development of differentiated antibody therapeutics in oncology and immunology disease areas. The company is headquartered in Suzhou, Jiangsu and currently employs 210 full-time employees. The company went IPO on 2020-12-10. The Company’s products primarily include BATOCLIMAB (HBM9161), HBM9378, HBM7020, TCE Program, PORUSTOBART (HBM4003), HBM7022 and others. The products are primarily used to treat generalized myasthenia gravis (gMG), chronic obstructive pulmonary disease (COPD), asthma, autoimmune diseases, melanoma, colorectal carcinoma (CRC) and solid tumors. The firm provides next-generation antibody and biotherapeutic solutions through proprietary antibody technology platforms including Harbour Mice, HBICE, HBICA and single B cell cloning platform.
02142.HK stock price ended at $12.66 on 星期三, after dropping 2.16%
On the latest trading day Jan 21, 2026, the stock price of 02142.HK fell by 2.16%, dropping from $12.82 to $12.66. During the session, the stock saw a volatility of 2.38%, with prices oscillating between a daily low of $12.60 and a high of $12.90. On the latest trading day, the trading volume for 02142.HK decreased by 2.2M shares, aligning with the declining prices, which may indicate weakening market confidence in the near term. In total, 1.3M shares were traded, with a market value of approximately $10.5B.